

# Laura Stronati

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/106761/publications.pdf>

Version: 2024-02-01

67  
papers

5,140  
citations

136950  
32  
h-index

102487  
66  
g-index

67  
all docs

67  
docs citations

67  
times ranked

11269  
citing authors

#	ARTICLE	IF	CITATIONS
1	Innovative method to grow the probiotic <i>Lactobacillus reuteri</i> in the omega3-rich microalga <i>Isochrysis galbana</i> . <i>Scientific Reports</i> , 2022, 12, 3127.	3.3	1
2	Colonic inflammation accelerates the progression of liver disease: A protective role of dipotassium glycyrrhizate. <i>Digestive and Liver Disease</i> , 2022, 54, 1084-1093.	0.9	2
3	Fecal and mucosal microbiota profiling in pediatric inflammatory bowel diseases. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 1376-1386.	1.6	12
4	Emerging Roles of Gut Virome in Pediatric Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4127.	4.1	20
5	Fecal High-Mobility Group Box 1 as a Marker of Early Stage of Necrotizing Enterocolitis in Preterm Neonates. <i>Frontiers in Pediatrics</i> , 2021, 9, 672131.	1.9	10
6	SERPINB12 as a possible marker of steroid dependency in children with eosinophilic esophagitis: A pilot study. <i>Digestive and Liver Disease</i> , 2020, 52, 158-163.	0.9	2
7	Necroptosis in Intestinal Inflammation and Cancer: New Concepts and Therapeutic Perspectives. <i>Biomolecules</i> , 2020, 10, 1431.	4.0	30
8	Intestinal Inflammation Alters the Expression of Hepatic Bile Acid Receptors Causing Liver Impairment. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2020, 71, 189-196.	1.8	12
9	Recent advances in potential targets for eosinophilic esophagitis treatments. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 421-428.	3.0	3
10	Mucosal healing in Crohn's disease: new insights. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 335-345.	3.0	13
11	Functional analysis of gut microbiota and immunoinflammation in children with autism spectrum disorders. <i>Digestive and Liver Disease</i> , 2019, 51, 1366-1374.	0.9	38
12	Low Dose of Dipotassium Glycyrrhizate Counteracts Atherosclerosis Progression in ApoE <sup>-/-</sup> Female Mice. <i>Journal of Vascular Research</i> , 2019, 56, 267-270.	1.4	1
13	Next-Generation Metagenomics: Methodological Challenges and Opportunities. <i>OMICS A Journal of Integrative Biology</i> , 2019, 23, 327-333.	2.0	47
14	Dipotassium Glycyrrhizate Improves Intestinal Mucosal Healing by Modulating Extracellular Matrix Remodeling Genes and Restoring Epithelial Barrier Functions. <i>Frontiers in Immunology</i> , 2019, 10, 939.	4.8	22
15	Quantitative Assessment of Shotgun Metagenomics and 16S rDNA Amplicon Sequencing in the Study of Human Gut Microbiome. <i>OMICS A Journal of Integrative Biology</i> , 2018, 22, 248-254.	2.0	159
16	Transcription Factor ZNF281: A Novel Player in Intestinal Inflammation and Fibrosis. <i>Frontiers in Immunology</i> , 2018, 9, 2907.	4.8	20
17	NOD2 and inflammation: current insights. <i>Journal of Inflammation Research</i> , 2018, Volume 11, 49-60.	3.5	121
18	Bifidobacteria and lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease: which strains act as health players?. <i>Archives of Medical Science</i> , 2018, 1, 81-87.	0.9	78

#	ARTICLE	IF	CITATIONS
19	Faecal high mobility group box 1 in children with celiac disease: A pilot study. <i>Digestive and Liver Disease</i> , 2018, 50, 916-919.	0.9	10
20	Serum Markers of Necrotizing Enterocolitis: A Systematic Review. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2017, 65, e120-e132.	1.8	28
21	RIP3 AND pMLKL promote necroptosis-induced inflammation and alter membrane permeability in intestinal epithelial cells. <i>Digestive and Liver Disease</i> , 2017, 49, 1201-1210.	0.9	56
22	Macrophage Activation in Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) Correlates with Hepatic Progenitor Cell Response via Wnt3a Pathway. <i>PLoS ONE</i> , 2016, 11, e0157246.	2.5	50
23	NOD2 Is Regulated By Mir-320 in Physiological Conditions but this Control Is Altered in Inflamed Tissues of Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 315-326.	1.9	56
24	Fecal HMGB1 Reveals Microscopic Inflammation in Adult and Pediatric Patients with Inflammatory Bowel Disease in Clinical and Endoscopic Remission. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2886-2893.	1.9	42
25	A Method to Exploit the Structure of Genetic Ancestry Space to Enhance Case-Control Studies. <i>American Journal of Human Genetics</i> , 2016, 98, 857-868.	6.2	21
26	The Identification and Pharmacological Characterization of 6-( <i>tert</i> -Butylsulfonyl)- <i>N</i> -(5-fluoro-1 <i>H</i> -indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 4867-4880.	6.4	100
27	NOD2 induces autophagy to control AIEC bacteria infectiveness in intestinal epithelial cells. <i>Inflammation Research</i> , 2016, 65, 803-813.	4.0	37
28	Recent advances in understanding the role of adipocytokines during non-alcoholic fatty liver disease pathogenesis and their link with hepatokines. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 393-403.	3.0	25
29	Krill oil reduces intestinal inflammation by improving epithelial integrity and impairing adherent-invasive <i>Escherichia coli</i> pathogenicity. <i>Digestive and Liver Disease</i> , 2016, 48, 34-42.	0.9	35
30	Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial. <i>PLoS ONE</i> , 2016, 11, e0168216.	2.5	83
31	Apoptosis, Necrosis, and Necroptosis in the Gut and Intestinal Homeostasis. <i>Mediators of Inflammation</i> , 2015, 2015, 1-10.	3.0	110
32	LPS-induced TNF- $\alpha$ factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease. <i>Oncotarget</i> , 2015, 6, 41434-41452.	1.8	100
33	Dipotassium glycyrrhizate via HMGB1 or AMPK signaling suppresses oxidative stress during intestinal inflammation. <i>Biochemical Pharmacology</i> , 2015, 97, 292-299.	4.4	29
34	Micronuclei and chromosome aberrations in subjects occupationally exposed to antineoplastic drugs: a multicentric approach. <i>International Archives of Occupational and Environmental Health</i> , 2015, 88, 683-695.	2.3	37
35	Plasma high mobility group box 1 protein reflects fibrosis in pediatric nonalcoholic fatty liver disease. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 763-771.	3.1	22
36	Neuroimmune interactions at different intestinal sites are related to abdominal pain symptoms in children with <i>IBS</i> . <i>Neurogastroenterology and Motility</i> , 2014, 26, 196-204.	3.0	54

#	ARTICLE	IF	CITATIONS
37	Role of HMGB1 as a Suitable Biomarker of Subclinical Intestinal Inflammation and Mucosal Healing in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1448-1457.	1.9	66
38	Advances in the medical management of paediatric IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 99-108.	17.8	35
39	Necroptosis Is Active in Children With Inflammatory Bowel Disease and Contributes to Heighten Intestinal Inflammation. <i>American Journal of Gastroenterology</i> , 2014, 109, 279-287.	0.4	170
40	Endoplasmic reticulum stress and unfolded protein response are involved in paediatric inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2014, 46, 788-794.	0.9	21
41	Lactoferrin prevents invasion and inflammatory response following <i>E. coli</i> strain LF82 infection in experimental model of Crohn's disease. <i>Digestive and Liver Disease</i> , 2014, 46, 496-504.	0.9	31
42	<i>Lactobacillus reuteri</i> ATCC55730 in Cystic Fibrosis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2014, 58, 81-86.	1.8	56
43	Associations between Genetic Polymorphisms in IL-33, IL1R1 and Risk for Inflammatory Bowel Disease. <i>PLoS ONE</i> , 2013, 8, e62144.	2.5	75
44	Dipotassium Glycyrrhizate Inhibits HMGB1-Dependent Inflammation and Ameliorates Colitis in Mice. <i>PLoS ONE</i> , 2013, 8, e66527.	2.5	54
45	Paediatric ulcerative colitis“can we predict proctocolectomy?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012, 9, 494-495.	17.8	3
46	Interactions Between Intestinal Microbiota and Innate Immune System in Pediatric Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, S64-S66.	2.2	30
47	Association Study of a Polymorphism in Clock Gene PERIOD3 and Risk of Inflammatory Bowel Disease. <i>Chronobiology International</i> , 2012, 29, 994-1003.	2.0	38
48	Usefulness of single-balloon enteroscopy in pediatric Crohn's disease. <i>Gastrointestinal Endoscopy</i> , 2012, 75, 80-86.	1.0	52
49	Characterization of adherent-invasive <i>Escherichia coli</i> isolated from pediatric patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 913-924.	1.9	98
50	Randomised clinical trial: the effectiveness of <i>Lactobacillus reuteri</i> ATCC 55730 rectal enema in children with active distal ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 327-334.	3.7	219
51	Fecal HMGB1 Is a Novel Marker of Intestinal Mucosal Inflammation in Pediatric Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2011, 106, 2029-2040.	0.4	112
52	Usefulness of wireless capsule endoscopy in paediatric inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2011, 43, 220-224.	0.9	40
53	A study protocol for the evaluation of occupational mutagenic/carcinogenic risks in subjects exposed to antineoplastic drugs: a multicentric project. <i>BMC Public Health</i> , 2011, 11, 195.	2.9	22
54	Incidence in pediatric IBD is rising: Help from health administrative data. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1048-1049.	1.9	8

#	ARTICLE	IF	CITATIONS
55	New Insights Into the Pathogenesis of Inflammatory Bowel Disease: Transcription Factors Analysis in Bioptic Tissues From Pediatric Patients. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2011, 52, 271-279.	1.8	14
56	Methotrexate in paediatric ulcerative colitis: a retrospective survey at a single tertiary referral centre. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1017-1022.	3.7	19
57	Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. <i>Nature Genetics</i> , 2010, 42, 1118-1125.	21.4	2,284
58	Altered expression of innate immunity genes in different intestinal sites of children with ulcerative colitis. <i>Digestive and Liver Disease</i> , 2010, 42, 848-853.	0.9	28
59	Crohn's Disease in Children. , 2010, , 169-185.		0
60	Activation of NOD2-mediated intestinal pathway in a pediatric population with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1145-1154.	1.9	50
61	Pediatric Inflammatory Bowel Diseases and the Risk of Lymphoma: Should We Revise Our Treatment Strategies?. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2009, 48, 257-267.	1.8	40
62	Mucosal NOD2 expression and NF- $\kappa$ B activation in pediatric Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 295-302.	1.9	32
63	Chromosome aberrations and telomere length modulation in bone marrow and spleen cells of melphalan-treated p53+/ $\Delta$ mice. <i>Environmental and Molecular Mutagenesis</i> , 2008, 49, 467-475.	2.2	8
64	Radioresistance in a tumour cell line correlates with radiation inducible Ku 70/80 end-binding activity. <i>International Journal of Radiation Biology</i> , 2008, 84, 265-276.	1.8	11
65	Use of chromosome painting for detecting stable chromosome aberrations induced by melphalan in mice. <i>Environmental and Molecular Mutagenesis</i> , 2005, 45, 419-426.	2.2	6
66	Evaluation of chromosome painting to assess the induction and persistence of chromosome aberrations in bone marrow cells of mice treated with benzene. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2004, 545, 1-9.	1.0	7
67	Expression and DNA binding activity of the Ku heterodimer in bladder carcinoma. <i>Cancer</i> , 2001, 92, 2484-2492.	4.1	25